Insight

Final Overall Survival Analysis of S1500 on Advanced Papillary Renal Cell Carcinoma by Pedro Barata et al.

Pedro Barata/LinkedIn

Jan 2, 2025, 15:38

Final Overall Survival Analysis of S1500 on Advanced Papillary Renal Cell Carcinoma by Pedro Barata et al.

Enrique Grande, Head of Oncology at MD Anderson Cancer Center, shared a post on LinkedIn about a recent paper by Pedro Barata et al. published in

“Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma”

Authors: Pedro Barata, Catherine Tangen, Melissa Plets, Naomi Balzer-Haas, Sumanta Pal et al.

More posts featuring Enrique Grande.

Enrique Grande, MD, PhD, MSc, is the Head of Oncology and an Adjunct Professor at the GU Medical Oncology Department at MD Anderson Cancer Center. He is also an Associate Professor at Francisco de Vitoria University.

Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit. He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE).

Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.

Pedro Barata is the Miggo Family Endowment Chair in Clinical Research and an Associate Professor at University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine in Cleveland, Ohio.

He serves as Director of Clinical Research for the GU Medical Oncology Program and Co-Leader of the Genitourinary (GU) Disease Team. Dr. Barata specializes in treating GU tumors and designing clinical trials, with a research focus on proof-of-concept trials, clinical biomarkers, and genomic-based therapies.